KKK
Kairos Pharma, Ltd.
No trades
No trades
Compare with Kairos Pharma, Ltd.
−1.95 USD
−5.45 M USD
0.00 USD
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
John S. Yu
Website
Headquarters
Los Angeles
Founded
2013
ISIN
US48301N2036
CUSIP
48301N203
FIGI
BBG01JLR1R85
Identifiers
ISIN US48301N2036
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of KAPA is 1.84 USD — it has increased by 10.18% in the past 24 hours. Watch Kairos Pharma, Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Kairos Pharma, Ltd. stocks are traded under the ticker KAPA.
KAPA stock has risen by 7.91% compared to the previous week, the month change is a −17.86% fall, over the last year Kairos Pharma, Ltd. has showed a −81.36% decrease.
We've gathered analysts' opinions on Kairos Pharma, Ltd. future price: according to them, KAPA price has a max estimate of 84.00 USD and a min estimate of 14.00 USD. Watch KAPA chart and read a more detailed Kairos Pharma, Ltd. stock forecast: see what analysts think of Kairos Pharma, Ltd. and suggest that you do with its stocks.
KAPA reached its all-time high on Sep 16, 2024 with the price of 28.00 USD, and its all-time low was 1.51 USD and was reached on Sep 2, 2026. View more price dynamics on KAPA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KAPA stock is 15.06% volatile and has beta coefficient of 3.17. Track Kairos Pharma, Ltd. stock price on the chart and check out the list of the most volatile stocks — is Kairos Pharma, Ltd. there?
Today Kairos Pharma, Ltd. has the market capitalization of 6.23 M, it has decreased by −9.34% over the last week.
Yes, you can track Kairos Pharma, Ltd. financials in yearly and quarterly reports right on TradingView.
Kairos Pharma, Ltd. is going to release the next earnings report on Dec 2, 2026. Keep track of upcoming events with our Earnings Calendar.
KAPA net income for the last quarter is −1.39 M USD, while the quarter before that showed −1.65 M USD of net income which accounts for 0.00% change. Track more Kairos Pharma, Ltd. financial stats to get the full picture.
No, KAPA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 5, 2026, the company has 4 employees. See our rating of the largest employees — is Kairos Pharma, Ltd. on this list?
Like other stocks, KAPA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kairos Pharma, Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kairos Pharma, Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kairos Pharma, Ltd. stock shows the sell signal. See more of Kairos Pharma, Ltd. technicals for a more comprehensive analysis.